Riik: Uus-Meremaa
keel: inglise
Allikas: Medsafe (Medicines Safety Authority)
Losartan potassium 25mg
Douglas Pharmaceuticals Limited
Losartan potassium 25 mg
25 mg
Film coated tablet
Active: Losartan potassium 25mg Excipient: Colloidal silicon dioxide Isopropyl alcohol Lactose Magnesium stearate Methylene chloride Microcrystalline cellulose Opadry white 20H58983 Pregelatinised maize starch Purified talc
Blister pack, Aluminium, 30 tablets
Prescription
Prescription
Ipca Laboratories Limited
Ranbaxy-Losartan is indicated for the treatment of hypertension. Ranbaxy-Losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy Ranbaxy-Losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ACE inhibitor. Switching patients with heart failure who are stable on an ACE inhibitor to Ranbaxy-Losartan is not recommended. Ranbaxy-Losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.
Package - Contents - Shelf Life: Blister pack, Aluminium - 30 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Aluminium - 90 tablets - 24 months from date of manufacture stored at or below 25°C
2007-10-17
DATA SHEET RANBAXY-LOSARTAN ® LOSARTAN POTASSIUM 12.5 mg, 25 mg, 50 mg, & 100 mg tablets _PRESENTATION _ Ranbaxy-Losartan 12.5 mg tablets are white to off-white, circular, biconvex, film- coated tablets embossed with “L1”on one side and plain on the other side. Ranbaxy-Losartan 25 mg tablets are white to off-white, circular, biconvex, film- coated tablets embossed with “L2”on one side and plain on the other side. Ranbaxy-Losartan 50 mg tablets are white to off-white, circular, biconvex, film- coated tablets embossed with “L3”on one side and plain on the other side. Ranbaxy-Losartan 100 mg tablets are white to off-white, circular, biconvex, film- coated tablets embossed with “L4”on one side and plain on the other side. Do not halve the tablets. Dose equivalence when the tablets are divided has not been established. _THERAPEUTIC CLASS _ Ranbaxy-Losartan (losartan potassium), the first of a new class of agents for the treatment of hypertension is an angiotensin II receptor (type AT 1 ) antagonist. Ranbaxy-Losartan also provides a reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy and renal protection for type 2 diabetic patients with proteinuria. _INDICATIONS _ HYPERTENSION Ranbaxy-Losartan is indicated for the treatment of hypertension. REDUCTION IN THE RISK OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY Ranbaxy-Losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy (see Race). HEART FAILURE Ranbaxy-Losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ACE inhibitor. Switching patients with heart failure who are stable on an ACE inhib Lugege kogu dokumenti